Category: Latest News
-
WTW AI Workforce Transformation Partnership With Softtek Targets Enterprise Implementation
WTW (NASDAQ:WTW) has partnered with Softtek to combine workforce strategy and organizational change expertise with AI engineering and implementation capabilities, targeting companies seeking to move AI transformation plans into operational deployment. Key Investor Takeaways Why WTW Stock Is in Focus WTW announced a strategic partnership with Softtek designed to help organizations implement AI-related workforce changes…
-
FirstService Residential EV Charging Program Participation Extends to Three Alexandria Communities
FirstService Residential-managed communities are participating in Alexandria’s EV charging initiative, giving three condominium communities access to technical support and potential reimbursement grants for charger installations. Key Investor Takeaways Why FSV Stock Is in Focus FirstService Residential said Marina Towers Condominium Association, Northampton Place Condominium and Parkfairfax Condominium have participated in the Plug in Alexandria program.…
-
Satellos Receives FDA Clearance to Study Forazapadin in FSHD
Satellos Bioscience Inc. (NASDAQ:MSLE) has received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application to evaluate forazapadin in facioscapulohumeral muscular dystrophy, or FSHD, according to a company statement. The clearance allows Satellos to proceed with clinical testing of forazapadin in FSHD and represents the second clinical indication being investigated…
-
Vistagen Presents Fasedienol Subgroup Data in Severe Social Anxiety Disorder
Vistagen (NASDAQ:VTGN) presented exploratory clinical data for its investigational fasedienol nasal spray at Psych Congress 2026 in New Orleans on September 24, reporting findings from subgroup analyses involving participants with very severe social anxiety disorder. The findings were derived from two randomised, double-blind, placebo-controlled clinical trials and included one post-hoc analysis and one prespecified subgroup…
-
Cullinan Therapeutics Plans Q4 2026 Clinical Data Updates Across Three T Cell Engager Programs
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) plans to report clinical data from three T cell engager programmes during the fourth quarter of 2026, covering candidates being evaluated in autoimmune diseases and acute myeloid leukaemia. The Cambridge, Massachusetts-based biopharmaceutical company expects to provide updates on velinotamig, CLN-978 and CLN-049 during November and December. The planned readouts involve investigational…
-
Acadia Pharmaceuticals Shares Fall After RADIANT Phase 2 Study Misses Primary Endpoint
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) shares fell 6% after the company reported results from its Phase 2 RADIANT study of remlifanserin in Alzheimer’s disease psychosis, with the trial missing its primary endpoint while meeting a key secondary measure at nominal statistical significance. The study evaluated 30 mg and 60 mg once-daily doses of remlifanserin against placebo.…
-
Uxin Shares Rise as Q2 Revenue Increases 74.9% and Company Issues Q3 Guidance
Uxin Limited (NASDAQ:UXIN) shares rose 11.93% on Thursday after the used-car retailer reported a 74.9% year-on-year increase in second-quarter revenue, while its gross margin turned negative and its adjusted EBITDA loss widened. For the quarter ended June 30, 2026, Uxin reported revenue of RMB1.15 billion ($169.7 million), compared with RMB658.3 million in the same period…
-
TD SYNNEX Shares Fall Premarket Despite Q3 Revenue and Earnings Above Estimates
TD SYNNEX Corporation (NYSE:SNX) shares fell 3.44% in premarket trading on Thursday after the company reported third-quarter fiscal 2026 revenue and adjusted earnings per share above analyst estimates and issued fourth-quarter guidance. For the quarter ended August 31, 2026, TD SYNNEX reported adjusted earnings per share of $5.68, compared with the analyst consensus estimate of…
-
Darden Restaurants Shares Fall as Q1 Revenue Misses Analyst Estimate
Shares in restaurant operator Darden Restaurants Inc. (NYSE:DRI) fell 5.6% in premarket trading on Thursday after the company reported first-quarter revenue below analyst expectations, while adjusted earnings per share matched the consensus estimate. For the quarter ended August 30, 2026, Darden reported adjusted earnings per share of $2.05, in line with the analyst estimate of…
-
BlackBerry Shares Rise Premarket After Q2 Revenue Reaches $163.3 Million
BlackBerry (NYSE:BB) shares rose more than 2% in premarket trading on Thursday after the company reported second-quarter revenue and adjusted earnings per share above analyst estimates and provided updated guidance for fiscal 2027. Adjusted earnings per share were $0.07, compared with the analyst estimate of $0.04. Revenue increased 26% year-on-year to $163.3 million, above the…